Seroprevalence of SARS-CoV-2 in Sweden, April 26 to May 9, 2021

A national point seroprevalence study of SARS-CoV-2 was conducted in Sweden in April–May 2021. In total, 2860 individuals 3 to 90 years old from a probability-based web panel were included. Results showed that an estimated 32.6% of the population in Sweden had detectable levels of antibodies, and am...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports 2022-06, Vol.12 (1), p.10816-10816, Article 10816
Main Authors: Beser, Jessica, Galanis, Ilias, Enkirch, Theresa, Kühlmann Berenzon, Sharon, van Straten, Edward, Duracz, Jan, Rapp, Marie, Zakikhany, Katherina, Mansjö, Mikael, Wigren Byström, Julia, Forsell, Mattias N. E., Groenheit, Ramona, Tegmark Wisell, Karin, Bråve, Andreas
Format: Article
Language:English
Subjects:
631/250
631/326
692/699
Age groups
Antibodies
Confidence intervals
Coronaviruses
COVID-19 vaccines
Humanities and Social Sciences
Infections
Informed consent
Laboratories
multidisciplinary
Participation
Population
Public health
Questionnaires
Science
Science (multidisciplinary)
Serology
Severe acute respiratory syndrome coronavirus 2
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A national point seroprevalence study of SARS-CoV-2 was conducted in Sweden in April–May 2021. In total, 2860 individuals 3 to 90 years old from a probability-based web panel were included. Results showed that an estimated 32.6% of the population in Sweden had detectable levels of antibodies, and among non-vaccinated 20.1% had detectable levels of antibodies. We tested for differences in seroprevalence between age groups and by sex and estimated seroprevalence among previously infected participants by time since reporting.
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-022-15183-w